News Release

Mallinckrodt Extends Deadline For 2015 Research Fellowship Program

ST. LOUIS, May 26, 2015 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading specialty biopharmaceutical company, today announced that it has extended the deadline for submitting applications to its Research Fellowship Awards program to July 31, 2015. The program awards grants to help fund projects in a variety of therapeutic areas.

The Mallinckrodt Research Fellowship Awards program is designed to further scientific knowledge and foster fellows and their education. The program will award a total of 25 positions. The program provides grants to academic or non-profit institutions and research personnel, such as fellows, junior clinicians, residents and post-doctoral researchers, pursuing a research-oriented career in the areas of clinical, translational or basic research. Research must be conducted at eligible institutions and fulfill an unmet medical need or address essential scientific questions.

Specifically, the 2015 Research Fellowship Award Program will support 25 fellows in the potential areas of:

  • Neurology – multiple sclerosis and infantile spasms
  • Nephrology – glomerular diseases and related disorders
  • Ophthalmology – inflammatory diseases of the eye 
  • Pulmonology – symptomatic sarcoidosis
  • Rheumatology – rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, dermatomyositis, polymyositis, ankylosing spondylitis
  • Central nervous system disorders causing severe spasticity
  • Acute pain – i.e., perioperative, multimodal

The award program has an annual value of $2 million. Each $80,000/year award is granted by an independent review committee on a competitive basis for a maximum of two academic years, with the first year guaranteed and the second year contingent on approval of a progress submission demonstrating progress towards the pre-stated research objectives.

Interested researchers may learn more by visiting the Mallinckrodt web site at

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; neonatal critical care respiratory therapies; and analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. To learn more about Mallinckrodt, visit


Rhonda Sciarra 
Communications Manager 

Meredith Fischer
Senior Vice President, Communications and Public Affairs

Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO

John Moten
Vice President, Investor Relations

Logo - 


To view the original version on PR Newswire, visit:

SOURCE Mallinckrodt Pharmaceuticals